123 related articles for article (PubMed ID: 21596673)
1. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.
Wing JB; Smart L; Borrow R; Findlow J; Findlow H; Heath AW; Read RC
Clin Infect Dis; 2011 Jun; 52(11):1317-23. PubMed ID: 21596673
[TBL] [Abstract][Full Text] [Related]
2. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
3. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
4. Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.
Findlow H; Borrow R; Hardelid P; Newton E; Frankland S; Naylor S; Miller E; Kaczmarski E; Read RC
Clin Vaccine Immunol; 2011 Mar; 18(3):424-9. PubMed ID: 21248159
[TBL] [Abstract][Full Text] [Related]
5. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
6. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
[TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
8. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
[TBL] [Abstract][Full Text] [Related]
9. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients.
Zlamy M; Elias J; Vogel U; Frosch M; Jeller V; Cortina G; Jungraithmayr T; Prelog M
Vaccine; 2011 Aug; 29(37):6163-6. PubMed ID: 21718742
[TBL] [Abstract][Full Text] [Related]
12. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.
Pichichero M; Papa T; Blatter M; Mitchell D; Kratz R; Sneed J; Bassily E; Casey J; Gilmet G
Pediatr Infect Dis J; 2006 Nov; 25(11):995-1000. PubMed ID: 17072120
[TBL] [Abstract][Full Text] [Related]
13. [Study on the bactericidal antibody against Neisseria meningitidis serogroup C strains after immunization with a divalent polysaccharide (A plus C) vaccine].
Xu L; Luo LZ; Zhu BQ; He L; Gao Y; Shao ZJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):619-21. PubMed ID: 19957632
[TBL] [Abstract][Full Text] [Related]
14. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies.
Rezaei N; Aghamohammadi A; Siadat SD; Nejati M; Ahmadi H; Moin M; Pourpak Z; Kamali S; Norouzian D; Tabaraei B; Read RC
Vaccine; 2007 Jul; 25(29):5308-14. PubMed ID: 17574314
[TBL] [Abstract][Full Text] [Related]
15. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
[TBL] [Abstract][Full Text] [Related]
16. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults.
Lakshman R; Burkinshaw R; Choo S; Finn A
Vaccine; 2002 Nov; 20(31-32):3778-82. PubMed ID: 12399209
[TBL] [Abstract][Full Text] [Related]
17. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
Kelly DF; Snape MD; Clutterbuck EA; Green S; Snowden C; Diggle L; Yu LM; Borkowski A; Moxon ER; Pollard AJ
Blood; 2006 Oct; 108(8):2642-7. PubMed ID: 16675705
[TBL] [Abstract][Full Text] [Related]
18. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?
Tsai TF; Borrow R; Gnehm HE; Vaudaux B; Heininger U; Desgrandchamps D; Aebi C; Balmer P; Pedersen RD; Fritzell B; Siegrist CA
Clin Vaccine Immunol; 2006 Aug; 13(8):854-61. PubMed ID: 16893984
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
[TBL] [Abstract][Full Text] [Related]
20. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates.
Carmenate T; Canaán L; Alvarez A; Delgado M; González S; Menéndez T; Rodés L; Guillén G
FEMS Immunol Med Microbiol; 2004 Apr; 40(3):193-9. PubMed ID: 15039094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
